H. Lundbeck A/s Class A · OMXCOP:HLUN_A
H. Lundbeck A/s Class A — Lundbeck — Investor Presentation (June 2026)
13 slides from H. Lundbeck A/s Class A's investor presentation, Jun 5, 2026
Slide 1: A new frontier in severe migraine prevention
A new frontier in severe migraine prevention Investor Call, June 5th, 2026 Geo Lei, living with migraine
Slide 2: Safe harbor/forward-looking statements
Safe harbor/forward-looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any stateme
Slide 3: Agenda for today
Agenda for today A new frontier in severe migraine prevention PROCEED: Clinical validation of a first- in-class mechanism Johan Luthman Maria Alfaiate Executive Vice President, Executive Vice President, Building a franchise for leadership in Head of Research & Head of Corporate, Development Portfoli
Slide 4: Bocunebart: A new frontier in severe migraine prevention
Bocunebart: A new frontier in severe migraine prevention PROCEED trial clinically supports the PACAP inhibition pathway, providing a path for Lundbeck's second pillar in migraine prevention alongside Vyepti Strategic proof First-in-class Differentiated point franchise With PROCEED, Lundbeck delivers
Slide 5: Significant unmet need remains in migraine
Significant unmet need remains in migraine Despite improved treatment options, migraine is still a huge challenge and key disabling condition globally DISEASE BURDEN Number two cause of years #2 lived with disability1 And the leading cause of disability worldwide for young women Carlos, living with
Slide 6: Bocunebart advances PACAP inhibition as a potential novel and differentiated approach
Bocunebart advances PACAP inhibition as a potential novel and differentiated approach to preventive treatment of migraine Why target PACAP? Why bocunebart? In migraine biology, PACAP has both overlapping and distinct roles Bocunebart neutralizes PACAP, preventing receptor activation.⁵ versus CGRP, s
Slide 7: Bocunebart is on track to be first-in-class
Bocunebart is on track to be first-in-class The positive results from PROCEED supports PACAP as a novel pathway in migraine prevention Bocunebart demonstrated clinical evidence in migraine prevention PROCEED IV met its primary endpoint† PROCEED Primary Efficacy1 Placebo Bocunebart Dose A Bocunebart
Slide 8: Chronic migraine remains a top disability, still unresolved
Chronic migraine remains a top disability, still unresolved Reversing the vicious cycle of sensitization is a main unmet need in severe migraine prevention PACAP as a CM Novel Target Bocunebart is hypothesized to raise attack threshold, thereby prolonging recovery time and reverse sensitization CM i
Slide 9: Bocunebart demonstrates strong Ph2 efficacy data in CM
Bocunebart demonstrates strong Ph2 efficacy data in CM1 In chronic migraine, bocunebart delivers >2 additional monthly migraine day reduction vs placebo in patients previously treated with other preventive agents HOPE and PROCEED Pooled post-hoc analysis in Chronic Migraine Clinically meaningful red
Slide 10: Positioned to be an alternative for underserved patients
Positioned to be an alternative for underserved patients Many people living with chronic migraine still strive for optimal control, despite currently-available advanced preventive therapy 80 million1 people worldwide live with chronic migraine ~ 12 million Chronic migraine A common and severe condit
Slide 11: A path to migraine franchise leadership
A path to migraine franchise leadership Potential First-in-class bocunebart and a powerful aCGRP, Vyepti, powered by a sophisticated IV commercial engine BUILDING A LEADING MIGRAINE FRANCHISE PACAP CGRP FOUNDATION EXPANSION Vyepti Bocunebart A powerful aCGRP Potential First-in-class aPACAP Trusted P
Slide 12: PROCEED supports the potential for severe migraine leadership
PROCEED supports the potential for severe migraine leadership Phase 3 ready with next update to be provided in 2H of 2026 Key takeaways Next steps Potential first-in-class anti-PACAP preventive Regulatory interactions PROCEED Phase 2b data support bocunebart’s phase 3 readiness and on phase III Prog
Slide 13: Q&A
Q&A 13